Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib
Open Access
- 1 July 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Arteriosclerosis, Thrombosis, and Vascular Biology
- Vol. 30 (7), 1430-1438
- https://doi.org/10.1161/atvbaha.110.207142
Abstract
Objective— To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on the ability of high-density lipoprotein (HDL) to promote net cholesterol efflux and reduce toll-like receptor–mediated inflammation in macrophages. Methods and Results— A total of 18 patients received niacin, 2 g/d, for 4 weeks; 20 patients received anacetrapib, 300 mg/d, for 8 weeks; and 2 groups (n=4 and n=5 patients) received placebo. HDL samples were isolated by polyethylene glycol precipitation or ultracentrifugation, tested for the ability to promote cholesterol efflux in cholesterol-loaded THP-I or mouse peritoneal macrophages, or used to pretreat macrophages, followed by lipopolysaccharide exposure. HDL cholesterol levels were increased by 30% in response to niacin and by approximately 100% in response to anacetrapib. Niacin treatment increased HDL-mediated net cholesterol efflux from foam cells, primarily by increasing HDL concentration, whereas anacetrapib treatment increased cholesterol efflux by both increasing HDL concentration and causing increased efflux at matched HDL concentrations. The increased efflux potential of anacetrapib-HDL was more prominent at higher HDL cholesterol concentrations (>12 μg/mL), which was associated with an increased content of lecithin–cholesterol acyltransferase (LCAT) and apolipoprotein E and completely dependent on the expression of ATP binding cassette transporters (ABCA1 and ABCG1). Potent antiinflammatory effects of HDL were observed at low HDL concentrations (3 to 20 μg/mL) and were partly dependent on the expression of ABCA1 and ABCG1. All HDL preparations showed similar antiinflammatory effects, proportionate to the HDL cholesterol concentration. Conclusion— Niacin treatment caused a moderate increase in the ability of HDL to promote net cholesterol efflux, whereas inhibition of cholesteryl ester transfer protein via anacetrapib led to a more dramatic increase in association with enhanced particle functionality at higher HDL concentrations. All HDLs exhibited potent ability to suppress macrophage toll-like receptor 4–mediated inflammatory responses, in a process partly dependent on cholesterol efflux via ABCA1 and ABCG1.Keywords
This publication has 54 references indexed in Scilit:
- Role of HDL, ABCA1, and ABCG1 Transporters in Cholesterol Efflux and Immune ResponsesArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- The role of dysfunctional HDL in atherosclerosisJournal of Lipid Research, 2009
- Effects of acceptor composition and mechanism of ABCG1-mediated cellular free cholesterol effluxJournal of Lipid Research, 2009
- Increased Inflammatory Gene Expression in ABC Transporter–Deficient MacrophagesCirculation, 2008
- Increased Cellular Free Cholesterol in Macrophage-specific Abca1 Knock-out Mice Enhances Pro-inflammatory Response of MacrophagesPublished by Elsevier BV ,2008
- Torcetrapib‐induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosteroneBritish Journal of Pharmacology, 2008
- Shotgun proteomics implicates protease inhibition and complement activation in the antiinflammatory properties of HDLJCI Insight, 2007
- Putting cholesterol in its place: apoE and reverse cholesterol transportJCI Insight, 2006
- HDL from CETP-deficient subjects shows enhanced ability to promote cholesterol efflux from macrophages in an apoE- and ABCG1-dependent pathwayJCI Insight, 2006
- High-Density Lipoproteins Inhibit Cytokine-Induced Expression of Endothelial Cell Adhesion MoleculesArteriosclerosis, Thrombosis, and Vascular Biology, 1995